These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 23744127)
1. Imaging of early modification in cardiomyopathy: the doxorubicin-induced model. Aissiou M; Périé D; Cheriet F; Dahdah NS; Laverdière C; Curnier D Int J Cardiovasc Imaging; 2013 Oct; 29(7):1459-76. PubMed ID: 23744127 [TBL] [Abstract][Full Text] [Related]
2. To study the usefulness and comparison of myocardial strain imaging by 2D and 3D echocardiography for early detection of cardiotoxicity in patients undergoing cardiotoxic chemotherapy. Alam S; Chandra S; Saran M; Chaudhary G; Sharma A; Bhandhari M; Vishwakarma P; Pradhan A; Sethi R; Dwivedi SK; Narain VS Indian Heart J; 2019; 71(6):468-475. PubMed ID: 32248920 [TBL] [Abstract][Full Text] [Related]
3. Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-points: rationale and design of the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study. Lotrionte M; Palazzoni G; Natali R; Comerci G; Abbate A; Di Persio S; Biondi-Zoccai GG Int J Cardiol; 2009 Jun; 135(1):72-7. PubMed ID: 18572266 [TBL] [Abstract][Full Text] [Related]
4. Strain Analysis in the Assessment of a Mouse Model of Cardiotoxicity due to Chemotherapy: Sample for Preclinical Research. Rea D; Coppola C; Barbieri A; Monti MG; Misso G; Palma G; Bimonte S; Zarone MR; Luciano A; Liccardo D; Maiolino P; Cittadini A; Ciliberto G; Arra C; Maurea N In Vivo; 2016; 30(3):279-90. PubMed ID: 27107087 [TBL] [Abstract][Full Text] [Related]
5. Cardiac magnetic resonance imaging for the assessment of the myocardium after doxorubicin-based chemotherapy. Lunning MA; Kutty S; Rome ET; Li L; Padiyath A; Loberiza F; Bociek RG; Bierman PJ; Vose JM; Armitage JO; Porter TR Am J Clin Oncol; 2015 Aug; 38(4):377-81. PubMed ID: 24192805 [TBL] [Abstract][Full Text] [Related]
6. The evaluation of doxorubicin-induced cardiotoxicity: comparison of Doppler and tissue Doppler-derived myocardial performance index. Ayhan SS; Özdemir K; Kayrak M; Bacaksiz A; Vatankulu MA; Eren Ö; Koc F; Duman C; Gülec H; Demir K; Ari H; Sönmez O; Gök H Cardiol J; 2012; 19(4):363-8. PubMed ID: 22825896 [TBL] [Abstract][Full Text] [Related]
7. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Ganz WI; Sridhar KS; Ganz SS; Gonzalez R; Chakko S; Serafini A Oncology; 1996; 53(6):461-70. PubMed ID: 8960141 [TBL] [Abstract][Full Text] [Related]
9. Acute cardiomyopathy following a single dose of doxorubicin in a patient with adult T-Cell leukemia/lymphoma. Farina K; Kalac M; Kim S J Oncol Pharm Pract; 2021 Jun; 27(4):1011-1015. PubMed ID: 32869692 [TBL] [Abstract][Full Text] [Related]
10. Adriamycin-induced myocardial toxicity: new solutions for an old problem? Outomuro D; Grana DR; Azzato F; Milei J Int J Cardiol; 2007 Apr; 117(1):6-15. PubMed ID: 16863672 [TBL] [Abstract][Full Text] [Related]
19. Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model. Lightfoot JC; D'Agostino RB; Hamilton CA; Jordan J; Torti FM; Kock ND; Jordan J; Workman S; Hundley WG Circ Cardiovasc Imaging; 2010 Sep; 3(5):550-8. PubMed ID: 20622140 [TBL] [Abstract][Full Text] [Related]
20. Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance. Gyöngyösi M; Lukovic D; Zlabinger K; Spannbauer A; Gugerell A; Pavo N; Traxler D; Pils D; Maurer G; Jakab A; Riesenhuber M; Pircher A; Winkler J; Bergler-Klein J Cardiovasc Res; 2020 Apr; 116(5):970-982. PubMed ID: 31346605 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]